FDA Approves Imaavy as First-Ever Treatment for Warm Autoimmune Hemolytic Anemia, Representing a Landmark Advancement for Patients
August 25, 2026
August 25, 2026
RARITAN, New Jersey, Aug. 25 -- Johnson and Johnson Innovative Medicine issued the following news release on Aug. 24, 2026:
* * *
FDA approves IMAAVY(R) (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
* IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell function
* * *
FDA approves IMAAVY(R) (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
* IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell function